BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Inclusion Criteria:

* Able and willing to provide written informed consent.
* Aged 18 years or older.
* Histologically confirmed advanced or metastatic malignancy eligible for an enrolling study cohort.
* Disease progression following, intolerance of, ineligibility for, or refusal of applicable standard therapy.
* At least one measurable lesion according to the response criteria specified in the protocol.
* Eastern Cooperative Oncology Group performance status of 0 or 1.
* Life expectancy of at least 12 weeks.
* Adequate organ function.
* Willing and medically suitable to provide required tumor or skin biopsies.
* Meets the disease-specific and treatment-history requirements of the applicable Phase 2a cohort.
* For Phase 2a Part C: Histologically confirmed platinum-resistant high-grade serous or clear-cell ovarian carcinoma, prior platinum-based treatment as specified in the protocol, and suitability for paclitaxel treatment.

Exclusion Criteria:

1\. Active central nervous system metastases or carcinomatous meningitis.

* Active or clinically significant autoimmune disease, immunodeficiency, or use of prohibited immunosuppressive treatment.
* Prior treatment-related toxicity not recovered to the level specified in the protocol.
* Prior anticancer therapy, radiotherapy, immunotherapy, investigational treatment, or live vaccine within the protocol-defined washout period.
* History of clinically significant immune-mediated toxicity, including pneumonitis, associated with previous immune-checkpoint inhibitor treatment.
* Uncontrolled or clinically significant cardiovascular disease, serious infection, or another condition that could compromise safety or study participation.
* Major surgery without adequate recovery.
* Prior allogeneic tissue or solid-organ transplantation or active graft-versus-host disease.
* Pregnancy or breastfeeding, or unwillingness to comply with protocol-defined contraceptive requirements.
* Known hypersensitivity to a study treatment or its components.
* Another active malignancy, except for protocol-defined permitted malignancies.
* Participation in another interventional clinical trial that conflicts with this study.
* Unable or unlikely to comply with study procedures and requirements.
* For Phase 2a Part C: Receipt of prohibited colony-stimulating factors within the protocol-defined period before treatment.